公开(公告)号：US20210353606A1

公开(公告)日：2021-11-18

申请号：US17257804

申请日：2019-07-03

申请人： HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH

发明人： Ahmed S.A. Ahmed ,  Martin Empting ,  Mostafa Hamed ,  Rolf W. Hartmann ,  Jörg Haupenthal ,  Thomas Hesterkamp ,  Ahmed A.M. Kamal ,  Christine K. Maurer ,  Teresa Röhrig ,  Christian Schütz ,  Samir Yahiaoui ,  Michael Zender

IPC分类号： A61K31/4439 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07D413/12 ,  C07D405/14 ,  A61P31/04 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06

摘要： The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.